TLSI
TriSalus Life Sciences Inc

285
Mkt Cap
$276.05M
Volume
25.00
52W High
$7.95
52W Low
$3.42
PE Ratio
-2.74
TLSI Fundamentals
Price
$5.53
Prev Close
$6.15
Open
$6.15
50D MA
$6.08
Beta
0.38
Avg. Volume
213,403.64
EPS (Annual)
-$1.31
P/B
-10.31
Rev/Employee
$267,554.54
Loading...
Loading...
News
all
press releases
TriSalus Life Sciences (NASDAQ:TLSI) Stock Rating Lowered by Wall Street Zen
Wall Street Zen cut shares of TriSalus Life Sciences from a "hold" rating to a "sell" rating in a research report on Saturday...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
TriSalus Life Sciences, Inc. (TLSI) Upgraded to Buy: Here's What You Should Know
TriSalus Life Sciences, Inc. (TLSI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks·6d ago
News Placeholder
TriSalus Life Sciences Announces Preliminary Fourth Quarter and Full-Year 2025 Results and 2026 Revenue Guidance
TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (TriSalus or the Company), an oncology focused medical technology company advancing novel drug delivery technologies alongside standard-of-care therapies...
Business Wire·8d ago
News Placeholder
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives Consensus Recommendation of "Hold" from Analysts
Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) have received a consensus recommendation of "Hold" from the five ratings firms that are presently covering the stock, MarketBeat...
MarketBeat·22d ago
News Placeholder
TriSalus Life Sciences (NASDAQ:TLSI) Given New $12.00 Price Target at Canaccord Genuity Group
Canaccord Genuity Group lifted their price target on shares of TriSalus Life Sciences from $11.00 to $12.00 and gave the stock a "buy" rating in a research note on Wednesday...
MarketBeat·1mo ago
News Placeholder
TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Symptomatic Thyroid Disease on December 15, 2025
TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (TriSalus or the Company), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients...
Business Wire·2mo ago
News Placeholder
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Given Average Rating of "Moderate Buy" by Brokerages
TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the five analysts that are currently covering the company, MarketBeat...
MarketBeat·2mo ago
News Placeholder
TriSalus Life Sciences (NASDAQ:TLSI) Upgraded by Wall Street Zen to Hold Rating
Wall Street Zen upgraded TriSalus Life Sciences from a "sell" rating to a "hold" rating in a research report on Friday...
MarketBeat·2mo ago
News Placeholder
FY2026 EPS Estimates for TLSI Increased by Cantor Fitzgerald
TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Free Report) - Equities researchers at Cantor Fitzgerald boosted their FY2026 earnings estimates for shares of TriSalus Life Sciences in a research note...
MarketBeat·2mo ago
News Placeholder
TriSalus Life Sciences Launches TriNav XP Infusion System to Expand Options for Pressure-Enabled Drug Delivery
TriSalus Life Sciences, an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, is pleased to announce the...
Business Wire·2mo ago
<
1
2
...
>

Latest TLSI News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.